HIF1A and neoplasm: Given that the hypoxic tumor microenvironment (TME) supports the growth and metastasis of pancreatic cancer cells [182], inactivation of hypoxia-inducible factor-1α (HIF-1α) with CRISPR/Cas9 is suggested as another rational therapeutic approach [183].